Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors

References

• MclnnesIBSchettGThe pathogenesis of rheumatoid arthritisN Engl J Med2011365232205221922150039
   PubMed Web of Science ®Google Scholar
• SmolenJSAletahaDKoellerMWeismanMHEmeryPNew therapies for treatment of rheumatoid arthritisLancet200737096021861187417570481
   PubMed Web of Science ®Google Scholar
• ThalayasingamNIsaacsJDAnti-TNF therapyBest Pract Res Clin Rheumatol201125454956722137924
   PubMed Web of Science ®Google Scholar
• TanakaTOgataANarazakiMTocilizumab for the treatment of rheumatoid arthritisExpert Rev Clin Immunol20106684385420979549
   PubMed Web of Science ®Google Scholar
• TanakaTNarazakiMKishimotoTTherapeutic targeting of the interleukin-6 receptorAnnu Rev Pharmacol Toxicol20125219921921910626
   PubMed Web of Science ®Google Scholar
• TanakaTOgataAKishimotoTTargeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and updateRheumatol Curr Res2013S4002
   Google Scholar
• SatoKTsuchiyaMSaldanhaJReshaping a human antibody to inhibit the interleukin-6 dependent tumor cell growthCancer Res19935348518568428365
   PubMed Web of Science ®Google Scholar
• JonesGSebbaAGuJComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnn Rheum Dis2010691889619297346
   PubMed Web of Science ®Google Scholar
• NishimotoNHashimotoJMiyasakaNStudy of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumabAnn Rheum Dis20076691162116717485422
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoKStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapyMod Rheumatol2009191121918979150
   PubMed Web of Science ®Google Scholar
• SmolenJSBeaulieuARubbert-RothAOPTION InvestigatorsEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trialLancet2008371961798799718358926
   PubMed Web of Science ®Google Scholar
• GenoveseMCMcKayJDNasonovELInterleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy studyArthritis Rheum200858102968298018821691
   PubMed Web of Science ®Google Scholar
• EmeryPKeystoneETonyHPIL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: results from a 24-week multicentre randomized placebo controlled trialAnn Rheum Dis200867111516152318625622
   PubMed Web of Science ®Google Scholar
• KremerJMBlancoRBrzoskoMTocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one yearArthritis Rheum201163360962121360490
   PubMed Web of Science ®Google Scholar
• WeinblattMEKeystoneECFurstDEAdalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialArthritis Rheum2003481354512528101
   PubMed Web of Science ®Google Scholar
• BreedveldFCWeismanMHKavanaughAFThe PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis Rheum2006541263716385520
   PubMed Web of Science ®Google Scholar
• MainiRSt ClariEWBreedveldFInfliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study GroupLancet199935491941932193910622295
   PubMed Web of Science ®Google Scholar
• BreedveldFCEmeryPKeystoneEInfliximab in active early rheumatoid arthritisAnn Rheum Dis200463214915514722203
   PubMed Web of Science ®Google Scholar
• KeystoneECGenoveseMCKlareskogLGolimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD StudyAnn Rheum Dis200968678979619066176
   PubMed Web of Science ®Google Scholar
• KeystoneEvan der HeijdeDMasonDJrCertolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis Rheum200858113319332918975346
   PubMed Web of Science ®Google Scholar
• MorelandLWSchiffMHBaumgartnerSWEtanercept therapy in rheumatoid arthritis. A randomized, controlled trialAnn Intern Med1999130647848610075615
   PubMed Web of Science ®Google Scholar
• KlareskogLvan der HeijdeDde JagerJPTEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigatorsTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet2004363941067568115001324
   PubMed Web of Science ®Google Scholar
• GabayCEmeryPvan VollenhovenRADACTA Study InvestigatorsTocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trialLancet201338198771541155023515142
   PubMed Web of Science ®Google Scholar
• BergmanGJHochbergMCBoersMWintfeldNKielhornAJansenJPIndirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugsSemin Arthritis Rheum201039642544120223500
   PubMed Web of Science ®Google Scholar
• Gallego-GalisteoMVilla-RubioAAlegre-del ReyEMarquez-FernandezERamos-BaezJJIndirect comparison of biological treatments in refractory rheumatoid arthritisJ Clin Pharm Ther201237330130721831256
   PubMed Web of Science ®Google Scholar
• TurkstraENgSKScuffhamPAA mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritisCurr Med Res Opin201127101885189721848493
   PubMed Web of Science ®Google Scholar
• SalliotCFinckhAKatchamartWIndirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysisAnn Rheum Dis201170226627121097801
   PubMed Web of Science ®Google Scholar
• OrmeMEMacgilchristKSMitchellSSpurdenDBirdASystematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70Biologics2012642946423269860
   PubMedGoogle Scholar
• PierreisnardAIssaNBarnetcheTRichezCSchaeverbekeTMeta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexateJoint Bone Spine201380438639223141718
   PubMed Web of Science ®Google Scholar
• JonesGDarian-SmithEKwokMWinzenbergTEffect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate?Biologics2012615516122848148
   PubMedGoogle Scholar
• EmeryPSebbaAHuizingaTWBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisAnn Rheum Dis201372121897190423918035
   PubMed Web of Science ®Google Scholar
• DougadosMKisselKSheeranTAdding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)Ann Rheum Dis2013721435022562983
   PubMed Web of Science ®Google Scholar
• TakahashiNKojimaTKanekoAClinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activityClin Rheumatol2014331394724057092
   PubMed Web of Science ®Google Scholar
• SchiffMHKremerJMJahreisAVernonEIsaacsJDvan VollenhovenRFIntegrated safety in tocilizumab clinical trialsArthritis Res Ther2011135R14121884601
   PubMed Web of Science ®Google Scholar
• GenoveseMCRubbert-RothASmolenJSLongterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposureJ Rheumatol201340676878023457383
   PubMed Web of Science ®Google Scholar
• KoikeTHarigaiMInokumaSEffectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in JapanJ Rheumatol2014411152324187110
   PubMed Web of Science ®Google Scholar
• SinghJAWellsGAChristensenRAdverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database Syst Rev2011162CD00879421328309
   PubMed Web of Science ®Google Scholar
• JainASinghJAHarms of tumor necrosis factor inhibitions in rheumatic diseases: a focused systematic review of the literatureImmunotherapy20135326529923444956
   PubMed Web of Science ®Google Scholar
• Gómez-ReinoJJCarmonaLValverdeVRMolaEMMonteroMDBIOBADASER GroupTreatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance reportArthritis Rheum20034882122212712905464
   PubMed Web of Science ®Google Scholar
• TubachFSalmonDRavaudPResearch Axed on Tolerance of Biotherapies GroupRisk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registryArthritis Rheum20096071884189419565495
   PubMed Web of Science ®Google Scholar
• van VollenhovenRFNishimotoNYamanakaHExperience with Mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety databaseAnn Rheum Dis200968Suppl 3567
   Google Scholar
• OgataAMoriMHashimotoSMinimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigensMod Rheumatol201020213013319898919
   PubMed Web of Science ®Google Scholar
• GoutTOstörAJNisarMKLower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature reviewClin Rheumatol201130111471147421833686
   PubMed Web of Science ®Google Scholar
• MclnnesIBThompsonLGilesJTEffect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled studyAnn Rheum Dis Epub12242013
   Google Scholar
• GreenbergJDReedGDecktorDCORRONA InvestigatorsA comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registryAnn Rheum Dis20127171134114222294625
   PubMed Web of Science ®Google Scholar
• MarchesoniAZaccaraEGorlaRTNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practiceAnn N Y Acad Sci2009117383784619758236
   PubMed Web of Science ®Google Scholar
• Du PanSMDehlerSCiureaASwiss Clinical Quality Management PhysiciansComparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritisArthritis Rheum200961556056819405000
   PubMed Web of Science ®Google Scholar
• IannoneFFerraccioliGGremeseELapadulaGGroup Italiano di Studio sulle Early Arthritis (GISEA)Drug survival on TNF inhibitors: 2003–2004 data from Italian National Register (GISEA Registry)Ann Rheum Dis Epub12242013
   Web of Science ®Google Scholar
• LeffersHCBØstergaardMGlintborgBThree-year drug survival and effectiveness of Abatacept and Tocilizumab in patients with rheumatoid arthritis treated in routine care. Results from the Nationwide Danish Danbio RegistryArthritis Rheum201365Suppl 10S612
   Google Scholar
• HetlandMLChristensenIJTarpUAll Departments of Rheumatology in DenmarkDirect comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registryArthritis Rheum2010621223220039405
   PubMed Web of Science ®Google Scholar
• HishitaniYOgataAShimaYRetention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritisScand J Rheumatol201342425325923470089
   PubMed Web of Science ®Google Scholar
• SakaiRTanakaMNankiTREAL Study GroupDrug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target moleculesAnn Rheum Dis201271111820182622504558
   PubMed Web of Science ®Google Scholar
• YoshidaKTokudaYOshikawaHAn observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safetyRheumatology (Oxford)201150112093209921890622
   PubMed Web of Science ®Google Scholar
• StrandVBurmesterGROgaleSDevenportJJohnAEmeryPImprovements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE studyRheumatology (Oxford)201251101860186922753773
   PubMed Web of Science ®Google Scholar
• FusamaMNakaharaHHamanoYImprovement of health status evaluated by Arthritis Impact Measurement Scale (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumabMod Rheumatol201323227628322669600
   PubMed Web of Science ®Google Scholar
• FeistERubbert-RothAKaufmannJEffectiveness after 4 and 24 weeks and safety of the novel interleukin-6 receptor inhibitors tocilizumab (TCZ) in patients with active rheumatoid arthritis (RA)–analysis of the patient-reported outcomes (PRO) in the TAMARA studyAnn Rheum Dis201069Suppl 3544
   Google Scholar
• ChauffierKSalliotCBerenbaumFEffect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysisRheumatology (Oxford)2012511606821515629
   PubMed Web of Science ®Google Scholar
• StrandVRentzAMCifaldiMAChenNRoySRevickiDHealth-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter studyJ Rheumatol2012391637222045836
   PubMed Web of Science ®Google Scholar
• CallhoffJWeißAZinkAListingJImpact of biologic therapy on functional status in patients with rheumatoid arthritis – a meta-analysisRheumatology (Oxford)201352122127213523946435
   PubMed Web of Science ®Google Scholar
• HuynhTØstergaardAEgsmoseCPatients and health professional preferences to route of administration of biologics agents for RA treatmentAnn Rheum Dis201372Suppl 3431
   Google Scholar
• BurmesterGRRubbert-RothACantagrelAA randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)Ann Rheum Dis2014731697423904473
   PubMed Web of Science ®Google Scholar
• OgataATanimuraKSugimotoTA phase 3 study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis (MUSASHI)Arthritis Care Res (Hoboken) Epub8272013
   Web of Science ®Google Scholar
• TsaoNWBansbackNJShojaniaKMarraCAThe issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritisBest Pract Res Clin Rheumatol201226565967623218430
   PubMed Web of Science ®Google Scholar
• HallertEHusbergMKalkanASkoghTBernfortLEarly rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA projectScand J Rheumatol Epub12192013
   Web of Science ®Google Scholar
• SoiniEJHallinenTAPuolakkaKVihervaaraVKauppiMJCost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritisJ Med Econ201215234035122168785
   PubMedGoogle Scholar
• DiamantopoulosABenucciMCapriSEconomic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in ItalyJ Med Econ201215357658522313326
   PubMedGoogle Scholar
• Navarro SarabiaFBlancoFJAlvaro GraciaJMEconomic evaluation of rheumatoid arthritis monotherapy with tocilizumab and adalimumabRev Esp Salud Publica2013874343350 Spanish24100773
   PubMed Web of Science ®Google Scholar
• NgoPSorathiaRCToddCJonesGNashPAustralian economic evaluation of tocilizumab (TCZ) monotherapy vs adalimumab (ADA) monotherapy in patients with rheumatoid arthritis (RA) based on the ADACTA trialInternal Medicine Journal2013431212
   Google Scholar
• PapadakisKMcNamaraSWintfeldNA UK cost-effectiveness analysis on the use of tocilizumab (Roactemra®) with methotrexate in the treatment of adults with moderate to severe active rheumatoid arthritis who have failed to respond adequate to one or more DMARDsAnn Rheum Dis201069Suppl 3389
   Google Scholar
• McNamaraSKPapadakisKNWintfeldNAn economic evaluation on the use of tocilizumab (Roactemra®) with methotrexate in the treatment of adults with moderate to severe active rheumatoid arthritis who have failed to respond adequately to an anti-TNF drugs in ScotlandAnn Rheum Dis201069Suppl 3389
   Google Scholar
• TanakaEInoueEHoshiDCost-effectiveness of a humanized anti-intereleukin-6 (IL-6) receptor monoclonal antibody, tocilizumab, in rheumatoid arthritis using IORRA cohort databaseAnn Rheum Dis201271Suppl 366822121127
   PubMed Web of Science ®Google Scholar
• SmolenJSLandeweRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis Epub10252013
   Google Scholar
• OgataAHiranoTHishitaniYTanakaTSafety and efficacy of tocilizumab for the treatment of rheumatoid arthritisClin Med Insights Arthritis Musculoskelet Disord20125274222438671
   PubMedGoogle Scholar
• FujimotoMSeradaSMiharaMInterleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responsesArthritis Rheum200858123710371919035481
   PubMed Web of Science ®Google Scholar
• KagariTDoiHShimozatoTThe importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritisJ Immunol200216931459146612133972
   PubMed Web of Science ®Google Scholar
• TanakaTCan IL-6 blockade rectify imbalance between Tregs and Th17 cells?Immunotherapy20135769569723829620
   PubMed Web of Science ®Google Scholar
• SamsonMAudiaSJanikashviliNBrief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in rheumatoid arthritis patientsArthritis Rheum20126482499250322488116
   PubMed Web of Science ®Google Scholar
• PesceBSotoLSabugoFEffect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patientsClin Exp Immunol2013171323724223379428
   PubMed Web of Science ®Google Scholar
• NieHZhengYLiRPhosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-a in rheumatoid arthritisNat Med201319332232823396208
   PubMed Web of Science ®Google Scholar
• CarboneGWilsonADiehlSABunnJCooperSMRinconMInterleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritisInt J Biol Sci20139327928823493630
   PubMed Web of Science ®Google Scholar
• RollPMuhammadKSchumannMIn vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartmentArthritis Rheum20116351255126421305508
   PubMed Web of Science ®Google Scholar
• MuhammadKRollPSeiboldTImpact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and mutational targeting in memory B cellsAnn Rheum Dis20117081507151021551509
   PubMed Web of Science ®Google Scholar
• NemethERiveraSGabayanVIL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidinJ Clin Invest200411391271127615124018
   PubMed Web of Science ®Google Scholar
• SongSNIwahashiMTomosugiNComparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patientsArthritis Res Ther2013155R14124286116
   PubMed Web of Science ®Google Scholar
• ObiciLMerliniGAA amyloidosis: basic knowledge, unmet needs and future treatmentsSwiss Med Wkly2012142w1358022653707
   PubMed Web of Science ®Google Scholar
• LaihoKTiitinenSKaarelaKHelinHIsomakiHSecondary amyloidosis has decreased in patients with inflammatory joint disease in FinlandClin Rheumatol199918212212310357116
   PubMed Web of Science ®Google Scholar
• ImmonenKFinnePGronhagen-RiskaCA marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases – data from nationwide registries in FinlandAmyloid2011181252821284495
   PubMed Web of Science ®Google Scholar
• TanakaTHagiharaKHishitaniYOgataATocilizumab for the treatment of AA amyloidosisGuvencIAAmyloidosis – An Insight to Disease of Systems and Novel TherapiesCroatiaINTECH Open Access Publisher2011155170
   Google Scholar
• OkudaYOhnishiMMatobaKComparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseasesMod Rheumatol201424113714324261770
   PubMed Web of Science ®Google Scholar
• NishidaSHagiharaKShimaYRapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatmentAnn Rheum Dis20096871235123619525413
   PubMed Web of Science ®Google Scholar
• HakalaMImmonenKKorpelaMVasalaMKauppiMJGood medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosisAnn Rheum Dis201372346446523148310
   PubMed Web of Science ®Google Scholar
• MiyagawaINakayamadaSSaitoKStudy on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosisMod Rheumatol Epub10212013
   Web of Science ®Google Scholar